May 10, 2018
Lilly buys ARMO for $1.6 billion
Eli Lilly will buy ARMO BioSciences for $50 per share, or approximately $1.6 billion, the companies said Thursday.
Pharmaceuticals, Biotechnology and Life Sciences
Tag: Eli Lilly
April 24, 2018
FDA’s Arthritis Advisory Committee recommends approval of Eli Lilly’s, Incyte Corporation’s 2-mg dose of baricitinib
Eli Lilly and Incyte Corporation scored a recommended approval of the 2-mg dose of a once-daily oral medication baricitinib from…
April 6, 2018
Encapsulated cell therapies for the potential treatment of type 1 diabetes from Lilly and Sigilon
Eli Lilly and Sigilon Therapeutics have announced a global collaboration to develop encapsulated cell therapies for the potential treatment of…
April 4, 2018
Phase 3 study in second-line liver cancer patients met overall survival endpoint
Eli Lilly has announced top-line results from its Phase 3 REACH-2 study of its second-line treatment for liver cancer CYRAMZA,…
February 13, 2018
Lilly’s Taltz meets enpoints in phase 3 study of Taltz for treating painful spine due to radiographic axial spondyloarthritis
Eli Lilly said on Tuesday that its Ankylosing Spondylitis treatment candidate, Taltz met the primary and all key secondary endpoints…
December 12, 2017
Lilly strengthens its oncology department with a new name
Eli Lilly said on Monday that Kimberly Blackwell, M.D., one of the USA’s leading breast cancer researchers, will join Lilly Oncology as…
December 12, 2017
FDA will review Eli Lilly’s Galcanezumab for the prevention of migraine in adults
Eli Lilly said on Monday that the U.S. Food and Drug Administration (FDA) has accepted a Biologics License Application (BLA) to review…
November 10, 2017
Eli Lilly’s Forteo reduces risk for new fractures in postmenopausal women with severe osteoporosis
Eli Lilly has reported new data showing that treatment with FORTEO for 24 months was associated with significantly fewer vertebral and clinical…
October 10, 2017
Diplomat to sell Eli Lilly’s new cancer drug
Diplomat Pharmacy will dispense newly approved Eli Lilly’s Verzenio(abemaciclib), a twice-daily oral therapy for advanced breast cancer. Verzenio is indicated…
September 29, 2017
Eli Lilly in leadership chances
Eli Lilly has made certain leadership changes, promoting several experienced Lilly leaders to executive roles, effective in 2018.